• Profile
Close

Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies

Clinical Rheumatology Sep 15, 2018

Fabiani C, et al. - In patients with refractory sight-threatening retinal vasculitis (RV), researchers assessed tumor necrosis factor (TNF)-α blockers adalimumab (ADA) and infliximab (IFX) for their effectiveness during a 12-month follow-up period. In addition, they evaluated any impact of concomitant conventional disease-modifying anti-rheumatic drugs (cDMARDs) and different lines of biologic therapy, any difference in effectiveness between ADA and IFX, consequences of biotherapies on the best-corrected visual acuity (BCVA), corticosteroid-sparing effect, and ocular complications during anti-TNF-α treatment. Findings suggest anti-TNF-α monoclonal antibodies have excellent results in these patients. They observed no differences in terms of RV resolution between patients taking monotherapy vs those co-administered cDMARDs at 3-month and 12-month follow-up, biologic-naïve patients vs those already exposed to other biologics at 3-month and 12-month visits, and patients treated with ADA vs those treated with IFX. Researchers noted a statistically significant corticosteroid-sparing effect, while there appeared no significant change in BCVA values.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay